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Abstract Objective: Aminosteroidal
and benzylisoquinoline neuromus-
cular blocking agents are used in
the intensive care unit to facilitate
mechanical ventilation. The use of
these agents has been associated
with development of critical illness
myopathy; however, the relative
frequency of myopathy development
among agents is not known. The
aim of our study was to compare the
effects of 24 h infusion of rocuronium
or cisatracurium on the diaphragm in
mechanically ventilated rats. Design:
Randomized, controlled experiment.
Setting: Basic animal science la-
boratory. Subjects: Male Wistar
rats, 14 weeks old. Interventions:
Rats were divided into four groups
to receive either saline, rocuronium
(low dose) or cisatracurium (low or
high dose). Measurements and re-
sults: After 24 h, in vitro diaphragm
tetanic force was decreased after
rocuronium (–33% vs. saline), while
the force was more preserved after
cisatracurium, even in the high-dose
group. Cross-sectional areas of the
different diaphragm and gastroc-
nemius fibers were unaltered. Di-
aphragmatic MURF-1 mRNA was
increased after rocuronium (+44%
vs. saline), while unchanged in both
cisatracurium groups. Calpain activ-
ity was increased after rocuronium
(+75% vs. saline) and unchanged in
the cisatracurium groups. MURF-1
mRNA expression and calpain activ-
ity were negatively correlated with
diaphragm force. Conclusions:
Cisatracurium infusion during con-
trolled mechanical ventilation exerted
less detrimental effects on diaphragm
function and proteolytic activity than
infusion of rocuronium, even with
the higher effective dose. These data
suggest that increased calpain activity
and increased activation of the ubiq-
uitin proteasome system play a role in
the different effects of these agents.
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Introduction
Sustained administration of non-depolarizing neuromus-
cular blocking agents (NMBAs) can be used to facilitate
mechanical ventilation (MV), assist in the treatment
of increased intracranial pressure, or reduce oxygen
consumption [1]. A large recent prospective cohort study
showed that these agents are used in 13% of MV patients
with a mean duration of 2 days [2]. In patients with acute
respiratory distress syndrome the frequency (± 25%)
and duration of NMBA use is even higher [3]. Both
aminosteroidal and benzylisoquinoline NMBAs are being
used for this purpose, and clinical preference for a specific
non-depolarizing NMBA is often based on the pharma-
cokinetic properties [4]. NMBA use is a known trigger for
myopathy development which can lead to prolonged MV
and intensive care unit (ICU) stay [1, 5]. After different
case reports, this myopathy was originally attributed
to the use of aminosteroidal NMBAs [3, 6]. However,
benzylisoquinoline agents have also been associated with
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myopathy development [7, 8]. Similar prevalence rates of
persistent muscle weakness were shown in patients treated
with vecuronium and atracurium (an aminosteroidal
and a benzylisoquinoline agent respectively) [9], but in
another prospective trial, no occurrence of myopathy was
described in 153 patients receiving benzylisoquinoline
agents [10].
Animal models of MV have shown that deleterious
effects of controlled MV (CMV), including reduction
in diaphragmatic force and fiber dimensions, developed
after only 18–72 h of CMV [11, 12]. Additionally, we
recently showed that rocuronium infusion during 24 h of
CMV led to an additional decrease in diaphragm force and
increased expression of diaphragmatic MURF-1 mRNA,
an E3-ligase of the ubiquitin–proteasome pathway,
suggesting enhanced muscle protein degradation after
rocuronium [13]. Whether these effects result from the
neuromuscular blocking process by itself and are induced
by all non-depolarizing NMBAs, or from a pleiotropic
effect of rocuronium, linked to its chemical structure,
has not yet been clarified. Since aminosteroidal agents
possess a steroid core and steroids are linked to myopathy
development [14], the aminosteroidal structure might be
responsible for the diaphragm dysfunction after rocuro-
nium infusion. In this case, benzylisoquinoline NMBAs,
with a similar neuromuscular blocking effect, would not
cause these deleterious effects even when administered at
a higher effective dose.
In the present study we compared the effects of two
non-depolarizing NMBAs: rocuronium, an aminosteroidal
NMBA and cisatracurium, a benzylisoquinoline derivative,
on diaphragm function, histology and expression of prote-
olysis markers, to examine the extent to which these two
NMBAs would affect diaphragm properties. In addition to
measuring MURF-1 expression, calpain activity and the
expression of its endogenous inhibitor, calpastatin, were
examined.
Some results of this study have been previously re-
ported in abstract form [15].
Materials and Methods
Experimental procedures, study design
The study was approved by the Animal Experiments Com-
mittee of the Medical Faculty of the Katholieke Univer-
siteit, Leuven.
The study was performed on anesthetized adult male
Wistar rats (14 weeks old) submitted to CMV for 24 h
and receiving a continuous infusion of either NaCl 0.9%
(n = 6), rocuronium in low dose (n = 6) or cisatracurium in
low dose (n = 7) or high dose (n = 5).
The experimental setup was adapted from previous
experiments [16]. Briefly, animals were anesthetized with
sodium pentobarbital (60 mg.kg–1 intraperitoneally) and
tracheotomized. The right jugular vein and carotid artery
were cannulated for infusion of sodium pentobarbital
(2 mg.100 g–1.ml–1) and heparin (2.8 U ml–1.h–1), re-
spectively, and the right lateral tail vein for infusion of
rocuronium, cisatracurium or NaCl 0.9%. Blood pressure
was checked every 2 h and blood gases every 12 h. Around
the left sciatic nerve, an electrode was implanted at the
upper thigh level which, when stimulated, caused plantar
flexion of the left foot [13]. Plantar flexion twitch, induced
by supramaximal stimulation, was measured before
infusion of rocuronium, cisatracurium or NaCl 0.9%, after
1 h, and then every 3 h. Rocuronium and cisatracurium
infusions were titrated to achieve a 50% (rocuronium and
low-dose cisatracurium) or 90% (high-dose cisatracurium)
reduction in twitch.
Electromyographic diaphragmatic activity was meas-
ured, as previously described, in three animals of each
group [13]. These measurements confirmed the absence
of diaphragmatic electrical activity during CMV in all
groups.
During the 24 h, continuing care to the animals was
performed including expressing the bladder and lubri-
cating the eyes. Animals breathed humidified air (37 °C)
enriched with O2. MV occurred in volume-control mode
(tidal volume: 0.6 ml.100 g–1 body weight, respiratory
rate: 60 min–1).
After 24 h, costal diaphragm segments were removed
for measurement of in vitro contractile properties as
previously described [17]. Briefly, two diaphragm bundles
per animal were suspended in a tissue bath (37 °C) con-
taining Krebs solution continuously aerated with 95% O2
and 5% CO2. Optimal length for peak twitch force was
verified, and after a 15-min thermoequilibration period
the force–frequency relationship was established by direct
bundle stimulation at the following frequencies: 1, 25, 50,
80, 120, and 160 Hz (250 ms train duration, 0.2 ms pulse
duration) and fatigue properties were measured (330-ms
stimulations at 25 Hz every 3 s for 5 min). Cross-sectional
area (CSA) was obtained by dividing bundle weight by
muscle specific density and optimal length. Forces were
expressed per unit CSA.
In addition, weights of the diaphragm, gastrocnemius
and soleus muscle were measured. One part of the costal
diaphragm was frozen in liquid nitrogen for further ex-
amination as described subsequently. The other part of the
costal diaphragm and the gastrocnemius muscle were fold,
cut transversely, and frozen in isopentane cooled with
liquid nitrogen to subsequently perform histological and
morphological analysis. Animals were killed by injecting
a sodium pentobarbital bolus into the heart.
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Histology and histochemistry
Sections of diaphragm and gastrocnemius were cut at
10 µm thickness with a cryostat maintained at –20 °C.
Sections were stained with hematoxylin and eosin (H&E)
and with myofibrillar adenosine triphosphatase (ATPase)
after acid preincubation at pH 4.5 and 4.3. CSA and
proportion of slow-twitch type I, fast-twitch type IIa
or IIx/b fibers were determined from the pixel number
within the outlined borders using a Leitz Laborlux X.
Microscope (Wetzlar, Germany) at × 20 magnification,
connected to a computerized image system (Quantimet
500, Leica, Cambridge, UK). Around 150 fibers were used
to calculate CSA of all fiber types and proportion.
RNA extraction and RT-PCR
Total diaphragm RNA was extracted using TRIzol. After
reverse transcription, semi-quantitative PCR was per-
formed with MAFbx and MURF-1 primers, with 18S
ribosomal RNA as internal standard. The 18S primers
were mixed with competimers at an optimized ratio of 1:9.
Amplification products were analyzed by electrophoresis
stained with Vistra Green and quantified by fluorescence
imaging (Photo-print, Vilber Lourmat, France). Intensi-
ties of the amplified fragments were normalized to the
corresponding 18S amplification signals.
Calpain activity and calpastatin expression
To assess diaphragm calpain activity, calpain-specific
cleavage products of αII-spectrin [18] were analyzed with
western blotting since activity assays are only reliable
with large tissue samples [19]. After diaphragm hom-
ogenization in KPO4 buffer, equal amounts of protein were
separated by SDS–polyacrylamide gel electrophoresis and
transferred by semidry blotting. Blots were exposed to
a monoclonal primary antibody to αII-spectrin (Biomol,
PA). After washing, a HRP-conjugated anti-mouse sec-
ondary antibody was applied (Dako, Denmark). Bands
Normal saline Rocuronium Low-dose High-dose
cisatracurium cisatracurium
Blood gases
PaO2 126±60 122±17 103±20 104±23
PaCO2 41±3 36±5 40±10 36±7
pH 7.42±0.05 7.47±07 7.42±0.04 7.42±0.08
Arterial blood pressure 90.83±11.03 103.2±6.08 101.00±8.47 99.00±13.19
Fiber type CSA
I 753±105 745±59 742±82 773±84
IIa 876±101 872±73 858±112 893±110
IIx/b 1853±156 1697±109 1857±129 1817±327
Table 1 Blood gas data, arterial
blood pressure at dissection time
and cross-sectional area (CSA)
of diaphragm fiber types I, IIa
and IIx/b in the normal saline,
rocuronium, low-dose
cisatracurium and high-dose
cisatracurium groups. Values are
mean ± SD expressed in torr for
blood gases and arterial blood
pressure and in µm2 for CSA
at 260 kDa represent intact αII-spectrin and bands at 150
and 145 kDa represent calpain-specific cleavage products
of αII-spectrin [20]. Cleaved bands were expressed as
percentage of intact bands and normalized as a percentage
of the normal saline group. Diaphragmatic calpastatin
expression was measured using polyclonal anti-calpastatin
(Sigma) and a HRP-conjugated anti-rabbit IgG (Dako) as
secondary antibody.
Statistical analysis
Statistical analysis was performed with the SAS statistical
package (SAS Institute Cary, NC, USA). Data were tested
for normality and equal variance. Comparisons among the
four groups were performed using ANOVA with post hoc
Newman–Keuls multiple comparison test. Correlations
were assessed with the Pearson correlation coefficient.
Data are presented as means ± SE, unless otherwise
specified.
Results
Blood gases, arterial blood pressure and infusion doses
Blood gas/pH homeostasis was similar in the dif-
ferent groups and was kept within the normal range
throughout the experiment. Mean arterial blood pressure
was not different between the four groups (Table 1). The
dose of sodium pentobarbital was similar in all groups
(1.44 mg.100 g–1.h–1, pooled values). Mean rocuronium
dose was 6.02 mg.kg–1.h–1. Mean cisatracurium doses
were 2.67 and 3.51 mg.kg–1.h–1 in the low-dose cisatra-
curium and high- dose cisatracurium groups, respectively
(p < 0.01).
Twitch of the gastrocnemius complex
Twitches decreased immediately to 50% of the initial value
in the rocuronium and low-dose cisatracurium groups and
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Fig. 1 In vitro force–frequency relationship of the diaphragm
expressed in absolute values in the normal saline (closed circles),
rocuronium (open circles), low-dose cisatracurium (closed squares)
and high-dose cisatracurium (open squares) groups. Values are
means and SE. *p < 0.01 rocuronium vs. normal saline, #p < 0.01
rocuronium vs. low-dose cisatracurium, ˆp < 0.05 rocuronium vs.
low-dose cisatracurium and high-dose cisatracurium, ◦p < 0.05
high-dose cisatracurium vs. normal saline, §p < 0.01 low-dose
cisatracurium vs. normal saline
to 10% of the initial value in the high-dose cisatracurium
group and were kept around this level during the entire ex-
periment. Twitches in rocuronium, low-dose cisatracurium
and high-dose cisatracurium groups were different at all
time points in comparison with the normal saline group.
There was no difference in twitch between the rocuronium
and low-dose cisatracurium groups.
Fig. 2 In vitro diaphragm tetanic force in the normal saline, rocuro-
nium, low-dose cisatracurium and high-dose cisatracurium groups
(same symbols as in Fig. 1). Each point represents an individual
animal. The horizontal line represents the mean value of the group.
*p < 0.01 vs. all other groups
Diaphragm contractile properties
In the rocuronium group, in vitro diaphragm force was
reduced in comparison with the normal saline group at
all stimulation frequencies (Fig. 1), including tetanic ten-
sion (Fig. 2). Compared with both cisatracurium groups,
diaphragm force in the rocuronium group was lower at
1 Hz and at the high stimulation frequencies (Fig. 1). In
comparison with the normal saline group, force was re-
duced in the low-dose cisatracurium group at 25 Hz and in
the high-dose cisatracurium group at the low stimulation
frequencies. Forces in low-dose cisatracurium and high-
dose cisatracurium groups were not different. The fatigue
properties of the diaphragm were similar in all the groups.
Histology of diaphragm and gastrocnemius
H&E staining revealed no pathologic changes in the dia-
phragm and the gastrocnemius muscle. The proportion of
diaphragm and gastrocnemius fibers remained unchanged
between the groups. There were no significant differences
in CSA of the different diaphragm and gastrocnemius
fiber types. However, CSA of type IIx/b fibers in the
diaphragm was non-significantly decreased in the rocuro-
nium group (–9%) in comparison with the normal saline
group (p > 0.05 vs. all groups) (Table 1).
Fig. 3 Diaphragm MURF-1/18S mRNA expression in the normal
saline (solid bar), rocuronium (open bar), low-dose cisatracurium
(vertically hatched bar) and high-dose cisatracurium (horizontally
hatched bar) groups. The left lane is the DNA ladder; the bottom
bands (315 bp) represent the 18S signal, the top bands (500 bp), the
MURF-1 signal of a representative animal in each group. Values are
means and SE, expressed as percentage of the normal saline group.
*p < 0.05 vs. normal saline and low-dose cisatracurium
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Fig. 4 Correlation between MURF-1 mRNA levels in the diaphragm
and diaphragm tetanic force in normal saline (closed circles), rocuro-
nium (open circles), low-dose cisatracurium (closed squares) and
high-dose cisatracurium (open squares) groups. The solid line and
dotted lines represent the regression line and 95% confidence inter-
vals, respectively
Expression of diaphragm MURF-1 and MAFbx/atrogin-1
mRNA
Expression of MAFbx mRNA was not different between
the groups. MURF-1 mRNA expression in the diaphragm
was increased by 44% (p < 0.05 vs. normal saline and
Fig. 5 Ratio of calpain-cleaved to total αII-spectrin present in the
diaphragm of animals in the normal saline, rocuronium, low-dose
cisatracurium and high-dose cisatracurium groups. Bars as in Fig.
3. Bands at 260 kDa represent intact αII-spectrin, and bands at 150
and 145 kDa represent calpain-cleaved αII-spectrin. Values (means
and SE) are expressed as a percentage of the normal saline group.
*p < 0.05 vs. all other groups
low-dose cisatracurium groups) in the rocuronium group
while it remained unchanged in both cisatracurium groups
(Fig. 3). There was an inverse correlation between dia-
phragmatic MURF-1 mRNA expression and diaphragm
tetanic force (r = –0.71, p = 0.0005) (Fig. 4). Similar corre-
lations were present for the other stimulation frequencies
(–0.71 < r < –0.42, p < 0.05) (data not shown).
Calpain activity in the diaphragm
The ratio of calpain-cleaved αII-spectrin to total αII-
spectrin, a reliable marker of calpain activity [20], was
higher in the diaphragm of the rocuronium group than
in all other groups (p < 0.05) while unchanged in both
cisatracurium groups (Fig. 5). An inverse correlation was
found between the diaphragmatic tetanic force and the
ratio of cleaved to total αII-spectrin in the diaphragm
(r = –0.49, p < 0.05). Diaphragm levels of the endogenous
calpain inhibitor calpastatin were similar among the four
groups (51379 ± 3491 AU, pooled values).
Discussion
Overview of the principal findings
This study shows for the first time a direct comparison of
the effects of two NMBAs with different chemical core
structure on the diaphragm. The data show that continuous
infusion of an aminosteroidal neuromuscular blocking
agent (i.e. rocuronium) during the course of 24 h of CMV
in rats is more deleterious for diaphragm force than con-
tinuous infusion of a similar effective dose of a benzyliso-
quinoline agent (i.e. cisatracurium). Even when the dose of
cisatracurium is increased, the effect on diaphragm force is
less detrimental than that of rocuronium at lower effective
dose. Moreover, rocuronium increased the expression
of MURF-1 mRNA and the calpain activity in the dia-
phragm, while there were no significant changes observed
in the diaphragm of the rats treated with cisatracurium.
These data suggest that the decreased diaphragm force
after rocuronium infusion is the consequence of a direct
effect of rocuronium on the muscle caused by an increased
myofilament cleavage and proteolysis. It appears from our
data that cisatracurium infusion during MV in rats is less
harmful for the diaphragm than rocuronium infusion.
Experimental model and clinical relevance
The same animal model as in our previous study was
used [13]. Electromyographic measurements confirmed
that diaphragm activity was silenced in the differ-
ent groups. The effective doses of rocuronium and
cisatracurium used in this study are comparable with those
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used by clinicians in the ICU (one to three twitches with
train-of-four testing) [3]. We chose rocuronium because
it is the latest available aminosteroidal agent which
has become popular for providing excellent intubating
conditions in ICU patients [21]. Cisatracurium was chosen
as the representative benzylisoquinoline agent because it
has a similar duration of action as rocuronium and is also
widely used in the ICU [22].
Guideline-based indications for the sustained use of
NMBAs in the ICU are facilitation of MV, treatment
of intracranial pressure and enhancement of oxygena-
tion [1]. A recent study by Arroliga et al. showed that
these agents were used in about 13% of mechanically
ventilated patients with a mean duration of 2 days [2], and
Prielipp et al. described that up to 10% of ICU patients
receive continuous administration of NMBAs for at least
24 h [23]. Moreover, NMBAs are used in about 25% of
mechanically ventilated patients with ARDS, especially
in the early phase [24]. Since diaphragm measurements
were performed after 24 h of MV and NMBA infusion,
we cannot rule out the possibility that longer duration
of cisatracurium infusion would exert greater effects on
the diaphragm, but in any case the effects of rocuronium
seem to be more marked for the same infusion duration.
Whether the detrimental effects of rocuronium are re-
versible or not was not the subject of this study and cannot
be concluded from these data.
NMBAs and muscle
Administration of NMBAs can lead to two patterns of
severe muscle weakness: prolonged paralysis, character-
ized by an increased recovery time due to accumulation
of NMBA or metabolites, and critical illness myopathy
(CIM), a disorder in which skeletal muscle becomes
electrically inexcitable even long after the NMBA and
its metabolites are eliminated [1, 25]. It was shown
that CIM developed more frequently in patients who
received NMBAs and that CIM significantly increased
the duration of MV [24]. The relative frequency of CIM
between different NMBAs has not yet been clarified.
Aminosteroidal and benzylisoquinoline agents have
both been associated with the development of CIM; in
clinical studies, however, confounding factors are often
present, such as co-administration of corticosteroids
or antibiotics [26]. In our study, diaphragm force was
significantly and severely reduced after 24 h infusion of
rocuronium in a dose which causes a 50% twitch reduction
of a peripheral muscle, while this reduction in diaphragm
force was less (lower stimulation frequencies) or not
present (higher stimulation frequencies) after infusion of
a functionally similar or higher dose of cisatracurium.
These findings point out that the effect of rocuronium on
the diaphragm is direct and not related to a subsequent
decrease in diaphragm activity. Moreover, EMG measure-
ments showed absence of diaphragmatic activity in all
groups.
Peripheral muscles of patients with CIM show pres-
ence of atrophy, especially of fast-twitch fibers [27]. In our
study, there was no significant difference in CSA of the
different fiber types among the groups. However, in accor-
dance with our previous study [13], a slightly decreased
CSA of type IIx/b fibers only was shown in the diaphragm
of the rocuronium group compared with the normal saline
group. The fact that NMBA infusion had no significant ef-
fect on diaphragm fiber CSA might be explained by the
relatively short study duration and the fact that 24 h of
CMV alone already induced atrophy of type I and IIx/b
fibers [28].
Muscle proteolysis
Studies regarding skeletal muscle wasting in conditions of
disuse and disease have shown that three proteolytic sys-
tems can induce muscle atrophy: the calcium-dependent
calpain system, the lysosomal protein system and the ubiq-
uitin–proteasome system. Diaphragm unloading by CMV
activates all these proteolytic systems [29–32]. Also, acti-
vation of the calpain and the ubiquitin–proteasome system
has been shown in CIM [33, 34].
MAFbx and MURF-1, two E3-ligases of the ubi-
quitin–proteasome system, have been identified as key
substrate-specific enzymes in the ubiquitination pro-
cess [35]. Regulation of these genes is used as a marker
of muscle atrophy in different conditions of disuse and
starvation [36]. In our study MURF-1 mRNA was up-
regulated in the rocuronium group, but unaltered in both
cisatracurium groups. MAFbx was not upregulated by
infusion of rocuronium or cisatracurium. The selective
upregulation of MURF-1 mRNA in animals treated with
rocuronium suggests activation of NFκB, since it was
previously shown that only MURF-1, and not MAFbx,
was upregulated in muscle of transgenic mice overex-
pressing active IκB kinase, which allows activation of
NFκB [37].
Since the ubiquitin–proteasome system is incapable
of degrading intact myofibrillar proteins, intact myofibrils
must first be cleaved by another proteolytic mechanism
to become a substrate for the proteasome system [32].
Hereby, the proteasome and the calpain system seem to be
regulated in parallel [38]. In agreement, an increased dia-
phragmatic calpain activity was found in the rocuronium
group together with an increased MURF-1 expression.
This increased calpain activity may lead to cleavage of
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intact myofibrils which can be further degraded by the
ubiquitin–proteasome system [39].
Normally, the calpain activity in muscle fibers is regu-
lated by interaction of the endogenous calpain inhibitor
calpastatin and by free cytosolic calcium [40]. Since cal-
pastatin protein levels did not differ among the four groups
in our experiment, the increased calpain activity is prob-
ably caused by disturbances in calcium homeostasis of the
muscle cells. Indirect evidence shows that intracellular cal-
cium levels are increased in the diaphragm after CMV [29].
Moreover, since corticosterone, the principal glucocorti-
coid in rats, increases calcium uptake in muscle cells and
aminosteroidal compounds are similar to corticosteroids
with regard to molecular structure, rocuronium infusion
could possibly be responsible for an increased intramus-
cular calcium level [22, 41].
The fact that diaphragmatic MURF-1 and the calpain
activity are not upregulated in the cisatracurium groups
underlines the importance of these markers in the patho-
physiology of the diaphragm dysfunction induced by
rocuronium.
Conclusions
In rats, 24 h infusion of cisatracurium, a benzylisoquino-
line NMBA, exerted less detrimental effects on diaphragm
function and proteolytic activity than rocuronium, an
aminosteroidal agent. The use of prolonged infusions
of rocuronium has been questioned recently because of
the potential drug accumulation in patients with renal
and/or hepatic failure [4]. Our data may provide another
argument against this practice. Whether the effects of
benzylisoquinoline and aminosteroidal drugs on diaphrag-
matic function and proteolytic activity also differ after
short-term use in humans seems an important question
that needs to be addressed in future studies.
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